Abstract
The combined use of a photosensitizing agent, light and dioxygen for the treatment of diseases has become known as photodynamic therapy (PDT) and was first discovered more than one hundred years ago. Over the years, PDT has proven its potential for the treatment of malignant and non-malignant lesions in addition to classical cancer therapy in numerous clinical studies, but application as a routine method is still limited. In this review, the development of modern PDT since the beginning of the twentieth century is briefly portrayed. The underlying mechanisms of phototoxicity are explained, and the requirements for ideal photosensitizers (PS) are underlined. Selected PS are introduced and examples of some of the many attempts made at the optimization of PDT by developing new PS with improved chemical and phototoxic properties, are reviewed. Promising 3rd generation PS are introduced and newer approaches to increasing tumor selectivity and efficacy of PDT, such as with nanoparticles, are discussed.
Keywords: Photodynamic therapy, photosensitizers, upconversion nanoparticles.
Current Pharmaceutical Design
Title:Photosensitizers for Photodynamic Therapy: Photochemistry in the Service of Oncology
Volume: 22 Issue: 46
Author(s): Carsten Lange and Patrick J. Bednarski
Affiliation:
Keywords: Photodynamic therapy, photosensitizers, upconversion nanoparticles.
Abstract: The combined use of a photosensitizing agent, light and dioxygen for the treatment of diseases has become known as photodynamic therapy (PDT) and was first discovered more than one hundred years ago. Over the years, PDT has proven its potential for the treatment of malignant and non-malignant lesions in addition to classical cancer therapy in numerous clinical studies, but application as a routine method is still limited. In this review, the development of modern PDT since the beginning of the twentieth century is briefly portrayed. The underlying mechanisms of phototoxicity are explained, and the requirements for ideal photosensitizers (PS) are underlined. Selected PS are introduced and examples of some of the many attempts made at the optimization of PDT by developing new PS with improved chemical and phototoxic properties, are reviewed. Promising 3rd generation PS are introduced and newer approaches to increasing tumor selectivity and efficacy of PDT, such as with nanoparticles, are discussed.
Export Options
About this article
Cite this article as:
Lange Carsten and Bednarski J. Patrick, Photosensitizers for Photodynamic Therapy: Photochemistry in the Service of Oncology, Current Pharmaceutical Design 2016; 22 (46) . https://dx.doi.org/10.2174/1381612822666161124155344
DOI https://dx.doi.org/10.2174/1381612822666161124155344 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The NPC1L1 Inhibitor Ezetimibe in the Treatment of the Dyslipidemia in Patients Affected by the Metabolic Syndrome: Evidences and Perspectives
Current Enzyme Inhibition The Role of Antioxidants in the Prevention of Cadmium-Induced Endothelial Dysfunction
Current Pharmaceutical Design Antioxidants in the Practice of Medicine; What Should the Clinician Know?
Cardiovascular & Hematological Disorders-Drug Targets Oxidative Stress and Cardiovascular Aging: Interaction Between NRF-2 and ADMA
Current Cardiology Reviews Bioactivity and Pharmacological Actions of Carbon Monoxide-Releasing Molecules
Current Pharmaceutical Design Role of Vascular Progenitor Cells in Cardiovascular Disease
Current Pharmaceutical Design The Role of Adipocytokines in Atherogenesis and Atheroprogression
Current Drug Targets Cross Talk between the Cardiovascular and Nervous Systems:Neurotrophic Effects of Vascular Endothelial Growth Factor (VEGF) and Angiogenic Effects of Nerve Growth Factor (NGF)-Implications in Drug Development
Current Pharmaceutical Design A Molecular Link Between Diabetes and Breast Cancer: Therapeutic Potential of Repurposing Incretin-based Therapies for Breast Cancer
Current Cancer Drug Targets Pharmacological Activity of Cardiovascular Agents from Herbal Medicine
Cardiovascular & Hematological Agents in Medicinal Chemistry The Potential Roles of Gamma-Glutamyltransferase Activity in the Progression of Atherosclerosis and Cardiovascular Diseases
Vascular Disease Prevention (Discontinued) Growth Factors in the Pathogenesis of Retinal Neurodegeneration in Diabetes Mellitus
Current Neuropharmacology Dyslipidaemia Related to Insulin Resistance and Cardiovascular Disease in South Asian and West African Populations
Current Pharmaceutical Design Cell-free DNA: Characteristics, Detection and its Applications in Myocardial Infarction
Current Pharmaceutical Design Glucocorticoids and the Cardiovascular System: State of the Art
Current Pharmaceutical Design Pharmacological Neuroprotection in Stroke: Rationale, State-of-the-art and Future Directions
Current Neuropharmacology Protective Effect of Vitamin B Therapy on Bone and Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Physiology of Folic Acid in Health and Disease
Current Drug Metabolism Duloxetine in the Treatment of Depression: An Overview
Central Nervous System Agents in Medicinal Chemistry Evolution of Biomarker Guided Therapy for Heart Failure: Current Concepts and Trial Evidence
Current Cardiology Reviews